Trial Profile
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo and Active-controlled, Parallel-group, Multicentre Clinical Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2022
Price :
$35
*
At a glance
- Drugs Opicapone (Primary) ; Benserazide; Carbidopa; Entacapone; Levodopa
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Acronyms BIPARK-I
- Sponsors Bial; BIAL - Portela C S.A.
- 18 Sep 2022 Results (n=237) of a Post-Hoc Analysis of BIPARK-I, presented at the 26th International Congress of Parkinson's Disease and Movement Disorders
- 06 Jun 2022 According to a Neurocrine Biosciences media release, Results of post-hoc analysis of ( NCT01568073 and NCT01227655) are being shared at SLEEP 2022, the annual meeting of the Associated Professional Sleep Societies, LLC (APSS) being held June 4-8 in Charlotte, North Carolina. The oral presentation of these data will take place on June 8
- 06 Jun 2022 Results of post-hoc analysis of ( NCT01568073 and NCT01227655) published in the Neurocrine Biosciences Media Release